GlassScriptPhysician profile
Safarez Semy
NPI 1780125898
$15,160.87
in general payments reported to CMS, 2019-2025
69 companies · $3,602 in 2025
The $3,602 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,534 · 2022: $3,205 · 2023: $2,958 · 2024: $2,862 · 2025: $3,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,308 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,308.45 |
| Education | $113.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.63 | 2021-2025 | |
| Sk Life Science, INC. | $1,161.80 | 2021-2025 | Xcopri |
| Pfizer INC. | $1,019.63 | 2021-2025 | |
| Biogen, INC. | $813.01 | 2021-2025 | Vumerity, Tysabri |
| Ucb, INC. | $776.40 | 2021-2025 | Rystiggo, Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $739.76 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $706.07 | 2022-2025 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $677.69 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Celgene Corporation | $408.98 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $399.44 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Emd Serono, INC. | $390.88 | 2021-2025 | Mavenclad, Mavenclad |
| Neurocrine Biosciences, INC. | $342.44 | 2021-2025 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $321.78 | 2021-2025 | Fycompa, Firdapse |
| Amneal Pharmaceuticals LLC | $304.65 | 2021-2025 | Rytary, Crexont |
| Biohaven Pharmaceuticals, INC. | $303.02 | 2021 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $289.04 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $283.77 | 2021-2025 | Ponvory |
| Lundbeck LLC | $270.26 | 2021-2025 | Rexulti |
| Janssen Biotech, INC. | $252.44 | 2025 | |
| Argenx US, INC. | $247.79 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Genzyme Corporation | $224.32 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $217.22 | 2022 | |
| Acadia Pharmaceuticals INC | $201.87 | 2022-2025 | Nuplazid, Daybue |
| Merz Pharmaceuticals, LLC | $193.38 | 2021-2024 | Xeomin, Ampyra, Inbrija |
| Mdd US Operations, LLC | $187.32 | 2021-2025 | Gocovri, Gocovri |
| Amgen INC. | $182.12 | 2021-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $174.37 | 2022-2025 | Kisunla, Amyvid |
| Neurelis, INC. | $169.57 | 2021-2025 | Valtoco |
| Abbott Laboratories | $150.56 | 2023-2024 | Infinity, Amplatzer Talisman |
| Grifols USA, LLC | $144.61 | 2021-2025 | Gamunex-C |
| Csl Behring | $141.28 | 2021-2024 | Hizentra |
| Livanova USA, INC. | $126.86 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $121.52 | 2021-2022 | |
| Kyowa Kirin, INC. | $119.85 | 2021-2024 | Nourianz |
| Upsher-Smith Laboratories LLC | $117.06 | 2021-2023 | |
| Axsome Therapeutics, INC. | $108.54 | 2023-2025 | Sunosi, Symbravo |
| Otsuka America Pharmaceutical, INC. | $105.44 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $102.99 | 2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $93.57 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $91.38 | 2021-2025 | Qelbree |
| Acorda Therapeutics, INC | $90.47 | 2021-2023 | Inbrija, Ampyra |
| Tonix Medicines, INC. | $78.93 | 2024-2025 | Zembrace Symtouch |
| Impel Pharmaceuticals INC. | $76.31 | 2022-2023 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $75.59 | 2021-2025 | Acthar |
| Impel Pharmaceuticals LLC | $74.11 | 2025 | Trudhesa |
| Tanabe Pharma America, INC. | $73.84 | 2022-2025 | Radicava |
| Cycle Pharmaceuticals INC | $69.38 | 2024-2025 | Tascenso Odt, Bafiertam |
| Alnylam Pharmaceuticals INC. | $56.89 | 2021-2024 | Onpattro |
| Ani Pharmaceuticals, INC. | $56.26 | 2025 | Purified Cortrophin Gel |
| Currax Pharmaceuticals LLC | $49.36 | 2021-2025 | Onzetra Xsail, Contrave |
| Ipsen Biopharmaceuticals, INC | $43.82 | 2021 | |
| Sunovion Pharmaceuticals INC. | $43.56 | 2021 | |
| Boston Scientific Corporation | $42.74 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $40.06 | 2021 | |
| Novo Nordisk INC | $39.78 | 2022-2025 | |
| Harmony Biosciences LLC | $35.56 | 2023-2024 | Wakix |
| Tg Therapeutics, INC. | $35.32 | 2024 | |
| Adamas Pharmaceuticals, INC. | $32.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.79 | 2021-2023 | Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $27.64 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $20.26 | 2022 | |
| Medtronic, INC. | $19.22 | 2023 | Percept PC Brainsense |
| Hikma Pharmaceuticals USA | $18.45 | 2023 | Mitigare |
| Esperion Therapeutics, INC. | $15.60 | 2021 | |
| Neuronetics, INC. | $14.71 | 2022 | |
| Glaxosmithkline, LLC. | $14.51 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Metacel Pharmaceuticals LLC | $14.35 | 2022 | |
| Amarin Pharma, INC. | $11.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Safarez Semy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.